Inhibrx Biosciences, Inc.INBXNASDAQ
LOADING
|||
Cash Flow Under Pressure
Below historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-197.01M
↓ 140% below average
Average (8y)
$-82.03M
Historical baseline
Range
High:$-18.32M
Low:$-197.90M
CAGR
+34.6%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-197.01M | +0.5% |
| 2023 | $-197.90M | -70.6% |
| 2022 | $-115.99M | -42.9% |
| 2021 | $-81.19M | -64.6% |
| 2020 | $-49.33M | -45.6% |
| 2019 | $-33.89M | -38.2% |
| 2018 | $-24.52M | -22.0% |
| 2017 | $-20.09M | -9.7% |
| 2016 | $-18.32M | - |